Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

The jaws of some sea worms are made of an exceptionally hard yet lightweight material dubbed a “bio-metal” that could have applications in engineering. Perinereis cultrifera is a type of ragworm with ...

Local and plentiful African padauk trees made durable roof shingles for the Ilima Elementary School, protecting against termites and the tropical climate. (MASS) The materials we build with shape far ...

The MarketWatch News Department was not involved in the creation of this content. -- First--in--class DARKFOX--targeting bispecific T cell engager: ENA101 is designed to selectively recognize the ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), today announced data from a benchmark study comparing key performance metrics of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is ...

Download this ebook to explore 50+ entrance exams after Class 12 for admission into top undergraduate colleges across engineering, management, law & more. No. Students will only be able to access and ...

The year was 2024. Deniz Kavi, a software engineer at Stanford School of Medicine, recalled the “untenable” research hand-off between wet lab biologists and computational scientists. The rise of ...

Light chain amyloidosis is not cancer, but cancer drugs are this rare disease’s standard of care. The patient need for new treatment options has sparked R&D efforts at biotech and big pharmaceutical ...

An illustration of a protein created by Accipiter Bio that has two active sites, shown in light and darker green, that can simultaneously bind two targets. (Accipiter Bio Image) A Seattle biotech ...